All In MedTech

Device Trial Radar · NCT07313800

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 1, 2028

Primary completion

Mar 1, 2030

Study completion Mar 1, 2032

Sponsor

Lead sponsor
Cortex NeurovascularNot on our public-company list
Sponsor type
Industry
First posted
Jan 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).

Conditions

  • Migraine Disorders
  • Refractory Migraine
  • Chronic Migraine

Interventions

  • TEMMA Endovascular TreatmentDevice

    Endovascular treatment targeting meningeal arterial contributors to migraine performed as part of the TEMMA procedure (Targeted Embolization for Migraine Management) using FDA-cleared devices. Procedural techniques and adjunctive assessments are individualized at the discretion of the treating physician and are not standardized within the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Monthly Headache Days Post-EmbolizationTime frame: Baseline to 12 months post-embolization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cortex Neurovascular / TRA Union

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.